Laurent Bentolila
Senior Researcher / Director
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (3)
Recording the neural activity of biological organisms is paramount in understanding how they process the world around them. Fluorescence microscopy has served as the standard in recording this neural activity due to its ability to capture large populations of neurons simultaneously. Recent efforts in fluorescence microscopy have been concentrated in imaging large scale volumes, however, most of these efforts have been limited by spatiotemporal and bandwidth constraints. We present a novel system called Transverse-Sheet Illumination Microscopy (TranSIM), which captures spatially separated planes onto multiple two-dimensional sCMOS sensors at near diffraction limited resolution with 1.0 µm, 1.4 µm, and 4.3 µm (x, y, and z respectively). The parallel use of sensors reduces the bandwidth bottlenecks typically found in other systems. TranSIM allows for the capturing of data at large-scale volumetric field-of-views up to 748 × 278 × 100 µm 3 at 100 Hz. Moreover, we were able to capture smaller field-of-views of 374 × 278 × 100 µm 3 at a faster volumetric rate of 200 Hz. Additionally, we found that the system’s versatile design allowed us the ability to change the vertical magnification programmatically rather than necessitating a change of objectives. With this system we were able to observe intricate communication between neuron populations separated by vast three-dimensional distances, raising the potential to answer complex questions in Neurobiology.
Year:
2025
Leucine-rich repeat containing 15 (LRRC15) has emerged as an attractive biomarker and target for cancer therapy. We have developed a humanized monoclonal antibody (mAb), DUNP19, that specifically binds to a phylogenetically conserved LRRC15 epitope and is internalized by target-expressing cancer and stromal cells. In xenograft mouse models, Lutetium-177 labeled DUNP19 ([ 177 Lu]-DUNP19) enables non-invasive imaging and precise radiotherapy to LRRC15-expressing cancer cells and murine cancer-associated fibroblasts (CAFs), halting tumor progression and prolonging survival with minimal toxicity. Transcriptomic analyses of [ 177 Lu]-DUNP19-treated tumors reveal a loss of pro-tumorigenic mechanisms, including a transforming growth factor beta (TGFβ)-driven and LRRC15+ signature associated with immunotherapy resistance. Together, these results demonstrate that radio-theranostic targeting of LRRC15 with DUNP19 is a compelling precision medicine platform for image-guided diagnosis, eradication, and reprogramming of LRRC15+ tumor tissue that drives immuno-resistance and aggressive disease. SIGNIFICANCE We introduce a pioneering LRRC15-guided radio-theranostic approach integrating clinical imaging and radioimmunotherapy. Our strategy utilizes a mAb, DUNP19, to target LRRC15-expressing cancer cells and fibroblasts, demonstrating significant tumor reduction, prolonged survival, and reversal of TGFβ-driven treatment resistance. This approach offers a promising strategy for improving outcomes in aggressive cancers.
Year:
2024
Year:
2023
Collaborators (11)
Claire Storey
Stanford University
Daniel Thorek
Associate Professor
Washington University in St. Louis
Alexa Sadier
Centre National de la Recherche Scientifique (CNRS)
Ken Herrmann
Chair
University Hospital Essen
Henrik Lilljebjörn
Lund University
Thomas Graeber
Professor
University of California, Los Angeles
Katsushi Arisaka
Professor
University of California, Los Angeles
Robert Damoiseaux
Professor & Director
UCLA Health
Thoas Fioretos
Professor, senior consultant
Lund University Medical Faculty
Jens Siveke
Director
Deutsches Krebsforschungszentrum
Katharina Lueckerath
Professor
University Hospital Essen
Make your next move.
Prepare your application
Review drafts before you send them.